Ornskov OK With Cinryze 'Cannibalization' As Shire Buys Dyax (And Keeps Baxalta Guessing)

03 Nov 2015

• By Sukaina Virji

Shire PLC is to acquire Dyax Corp. for $37.30 in cash per Dyax share, valuing the US biotech at around $5.9bn upfront. Dyax's promising hereditary angioedema (HAE) treatment DX-2930 could generate annual global sales "of up to $2.0bn" if approved for the prevention of type 1 and type 2 HAE, according to Shire. It is likely some of this revenue would come from "cannibalizing" Shire's current successful HAE treatment Cinryze (C1 esterase inhibitor [human]), but this doesn't concern CEO Flemming Ornskov.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

18 Apr 2025

• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.